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Abstract: (1) Background: Recently, a series of clinical neuroimaging studies on fibromyalgia (FM) have
shown a reduction in cortical volume and abnormally high glutamate (Glu) and glutamate + glutamine
(Glx) levels in regions associated with pain modulation. However, it remains unclear whether the
volumetric decreases and increased Glu levels in FM are related each other. We hypothesized that
higher Glu levels are related to decreases in cortical thickness (CT) and volume in FM patients.
(2) Methods: Twelve females with FM and 12 matched healthy controls participated in a session of
combined 3.0 Tesla structural magnetic resonance imaging (MRI) and single-voxel MR spectroscopy
focused on the thalami and ventrolateral prefrontal cortices (VLPFC). The thickness of the cortical
and subcortical gray matter structures and the Glu/Cr and Glx/Cr ratios were estimated. Statistics
included an independent t-test and Spearman’s test. (3) Results: The Glu/Cr ratio of the left VLPFC
was negatively related to the CT of the left inferior frontal gyrus (pars opercularis (p = 0.01; r = −0.75)
and triangularis (p = 0.01; r = −0.70)). Moreover, the Glx/Cr ratio of the left VLPFC was negatively
related to the CT of the left middle anterior cingulate gyrus (p = 0.003; r = −0.81). Significantly lower
CTs in FM were detected in subparts of the cingulate gyrus on both sides and in the right inferior
occipital gyrus (p < 0.001). (4) Conclusions: Our findings are in line with previous observations that
high glutamate levels can be related, in a concentration-dependent manner, to the morphological
atrophy described in FM patients.
Keywords: fibromyalgia; glutamate excitotoxicity; cortical thickness; brain MRI; chronic pain;
MR spectroscopy
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1. Introduction
Fibromyalgia (FM) is a disease characterized by chronic, widespread non-articular pain and
diffuse pain to light palpation without an identifiable peripheral pathology [1]. The individual nature
and the extreme heterogeneity of FM symptoms have led to a discussion regarding the nature of
this condition. However, there is general consensus that it represents a type of central sensitization
that results in chronic pain [2]. In other words, intense and protracted pain processing can give
rise to neuroplastic changes that perpetuate central sensitization [3,4]. Over the past decade, a few
proton magnetic resonance spectroscopy (H-MRS) studies have demonstrated changes in cerebral
metabolites in FM patients [5]. These results have reinforced the hypothesis of a neural dysfunction
underlying pain processing. In particular, a mismatch between excitatory (glutamate/glutamine)
and inhibitory neurotransmitters (gamma-aminobutyric acid, GABA) has been posited as a central
pathophysiological mechanism in FM [6]. These alterations seem to have an effect both on lowered
pain thresholds and the genesis of chronic pain. Higher glutamate (Glu) and Glu + glutamine (Glx)
levels in patients with FM have been consistently found and reported to positively correlate with
clinical pain scores [5]. Comparative studies have also shown that the accumulation of extracellular
Glu is toxic to neurons, leading to neuronal damage [7]. In particular, abnormally high levels of Glu,
resulting from increased release and/or decreased synaptic removal, can cause, in a dose-dependent
manner [8], the degeneration and death of neurons [9,10]. A separate line of research has also shown
that FM patients display volume reductions in a series of cortical and subcortical regions that have
been collectively linked to pain processing and modulation. These regions include the anterior and
posterior cingulate cortex, nucleus accumbens, amygdala, insula, caudate nucleus, prefrontal areas
and occipital cortex [11]. However, the potential association between brain structural changes and
Glu levels in FM has not been studied yet. This is surprising given the pre-clinical evidence showing
that the Glu concentration is toxic and can lead to neuronal degeneration [7–10]. To address this issue,
we recruited a sample of patients with FM and compared them with age- and sex-matched healthy
controls (HC), in terms of cortical volumetric alterations and Glu metabolic changes. Next, and more
importantly, we assessed if structural brain changes are related to Glu levels within the group of
patients alone. We hypothesized that higher within-patient levels of Glu related to greater neuronal
loss and damage, as assessed by sub-cortical volumetric measures and cortical thickness (CT) indices
derived from structural magnetic resonance imaging (MRI).
2. Materials and Methods
2.1. Subjects
The institutional review board of our hospital approved this retrospective study (Etic Committee:
APSS, protocol 4879/2019). All participants provided written informed consent prior to any study
procedures. Twelve patients (11 F, 1 M; 30–54 years; mean age 43.2 years) and 12 healthy controls
(HC) matched for sex and age (28–56 years; mean age 41.3 years) were recruited (see Table 1). The FM
patients met the 1990 American College of Rheumatology criteria for diagnosis of FM [1], without any
comorbidity (other rheumatologic diseases and/or central nervous system pathologies). All patients
studied where adopted from our previous report [12], but the present is a new investigation of the
relationship between the structural data and metabolites levels which was conducted concurrently,
but not previously reported. In particular, all patients suspended pharmacologic therapies that are
known to affect brain function a week before the study to avoid possible biases, with the exception of
acetaminophen, which was permitted to control pain. None of the control subjects took drugs or illicit
substances that affected cognitive functions or brain metabolites.
2.2. Brain Imaging and Spectroscopy
All MR imaging were performed by using a 3.0 Tesla whole-body scanner (Signa EXCITE; GE
Healthcare, Milwaukee, Wisconsin) equipped with an 8-channel standard phased array head coil.
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T2-weighted fast spin echo (FSE) sequences were acquired in the axial and coronal planes, while a
3D T1-weighed fast spoiled gradient recalled echo (FSPGR), with an isotropic voxel, was obtained
with reconstructions on the axial and coronal planes. A point resolved spectroscopy (PRESS) pulse
sequence (TR 2000 ms; TE 35 ms; 128 acquisitions) was used to generate the spectra of the volumes of
interest (VOI; 1.8 and 2.1 cm3). The voxels of interest (VOIs) were placed bilaterally on the thalamus
and ventrolateral prefrontal cortex (VLPFC), respectively, using the 3D FSPGR and FSE structural
scans as references to avoid sampling contaminations by bone, vascular and cerebrospinal fluid (CSF)
structures (Figure 1).
Table 1. Demographic and clinical data of twelve patients (Pt) suffering from fibromyalgia and twelve
healthy controls (HC).
No. of HC Age,Year Sex No. of Pt
AGE,
Year Sex
Onset,
Year
Duration,
Year TP VAS FIQ
1 33 F 1 34 F 30 4 11 47 48.4
2 54 F 2 54 F 45 9 18 87 83.15
3 41 F 3 44 F 40 4 18 36 38
4 45 F 4 45 F 42 3 18 70 67.86
5 40 F 5 39 F 36 3 16 50 44
6 48 F 6 49 F 47 1.5 16 80 69.77
7 49 F 7 49 F 42 7 12 85 61
8 45 F 8 45 F 44 1 18 90 74.21
9 41 F 9 39 F 30 9 11 54 58
10 50 F 10 53 F 50 3 12 54 37
11 49 F 11 48 F 47 1 14 60 47
12 52 M 12 41 M 35 6 18 90 80.44
TP (number of tender Points); VAS (visual analogic scale); FIQ (Fibromyalgia Impact Questionnaire).
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Figure 1. Axial T2-weighted fast spin echo (FSE) and sagittal 3D fast spoiled gradient recalled (FSPGR) 
images showing voxels of interest (VOIs) placement in the right ventrolateral prefrontal cortex 
(VLPFC) (a,b) and left thalamus (c,d). 
Detail on spectra acquisition and processing techniques were previously described [12]. The raw 
data from each spectrum were evaluated with LCModel 6.1 (Stephen Provencher, Oakville, Ontario, 
Canada),a user-independent fitting routine based on a library of model spectra of all individual 
metabolites [13]. The data evaluation comprised a correction of the spectroscopic time domain data for 
residual eddy current effects. Values for Glu, Gln and Glx (glutamate + glutamine) were calculated as 
ratios to an internal standard, the creatine (Cr) level, in the form Glu/Cr, Gln/Cr and Glx/Cr. Thus, we 
did not correct for cerebrospinal fluid (CSF) levels. 
2.3. Cortical and Subcortical Segmentations 
The FreeSurfer image analysis suite (version 5.3.0) (http://surfer.nmr.mgh.harvard.edu/) was 
used to extract the cortical and subcortical thickness estimations. The detailed procedure for surface 
reconstruction with FreeSurfer has been previously described and validated elsewhere [14–16]. In 
brief, the pipeline involves the removal of non-brain tissue, automated Talaraich transformation, 
segmentation of white and grey matter (GM), tessellation of the grey/white matter boundary, 
automated correction of the topology defects, surface deformation to form the grey/white matter 
boundary and grey/cerebrospinal fluid boundary, and parcellation of the cerebral cortex. Next, 
cortical thickness (CT) estimates were calculated as the distance between the grey/ white matter 
border and the pial surface at each vertex. Finally, mean CT values were extracted based on the 
Destrieux et al. atlas [17]. Subcortical volumes were calculated with FreeSurfer’s automated 
procedure for volumetric measures [18]. Each voxel in the normalized brain volume was assigned to 
one label using a probabilistic atlas obtained from a manually labeled training set. All processed 
images were visually inspected by a neuroradiologist with 15 years’ experience in conventional and 
advanced neuroimaging techniques, to confirm proper segmentation. 
Figure 1. Axial T2-weighted fast spin echo (FSE) and sagittal 3D fast spoiled gradient recalled (FSPGR)
images showing voxels of interest (VOIs) placement in the right ventrolateral prefrontal cortex (VLPFC)
(a,b) and left thalamus (c,d).
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Detail on spectra acquisition and processing techniques were previously described [12].
The raw data from each spectrum were evaluated with LCModel 6.1 (Stephen Provencher,
Oakville, Ontario, Canada), a user-independent fitting routine based on a library of model spectra of
all individual metabolites [13]. The data evaluation comprised a correction of the spectroscopic time
domain data for residual eddy current effects. Values for Glu, Gln and Glx (glutamate + glutamine)
were calculated as ratios to an internal standard, the creatine (Cr) level, in the form Glu/Cr, Gln/Cr and
Glx/Cr. Thus, we did not correct for cerebrospinal fluid (CSF) levels.
2.3. Cortical and Subcortical Segmentations
The FreeSurfer image analysis suite (version 5.3.0) (http://surfer.nmr.mgh.harvard.edu/) was
used to extract the cortical and subcortical thickness estimations. The detailed procedure for surface
reconstruction with FreeSurfer has been previously described and validated elsewhere [14–16].
In brief, the pipeline involves the removal of non-brain tissue, automated Talaraich transformation,
segmentation of white and grey matter (GM), tessellation of the grey/white matter boundary, automated
correction of the topology defects, surface deformation to form the grey/white matter boundary and
grey/cerebrospinal fluid boundary, and parcellation of the cerebral cortex. Next, cortical thickness (CT)
estimates were calculated as the distance between the grey/white matter border and the pial surface at
each vertex. Finally, mean CT values were extracted based on the Destrieux et al. atlas [17]. Subcortical
volumes were calculated with FreeSurfer’s automated procedure for volumetric measures [18].
Each voxel in the normalized brain volume was assigned to one label using a probabilistic atlas
obtained from a manually labeled training set. All processed images were visually inspected by a
neuroradiologist with 15 years’ experience in conventional and advanced neuroimaging techniques, to
confirm proper segmentation.
In the present study, we focused our attention first on the pain-processing regions studied with
the spectroscopy technique (VLPFCs—which are located in the inferior frontal gyrus—and thalami)
and previously reported to be involved in FM and chronic pain, including: cingulate cortex subparts,
insular cortex, temporal cortex and occipital cortex. The analysis of subcortical structures included the
bilateral caudate, putamen, thalamus and brainstem.
2.4. Statistical Analysis
All statistical analyses were run in R v. 3.6.1 (https://www.r-project.org). Differences in the CT
and volumes of subcortical structures between the two groups were compared using an independent
t-test. In the group of patients, Spearman’s rho was calculated to assess the relationship between the
cerebral structural measurements of the VLPFCs, thalami and their corresponding Glu/Cr, Gln/Cr
and Glx/Cr ratios. Since high levels of Glx/Cr were previously reported on the cingulate cortex of
FM patients [5], which is one of the key regions of pain processing, we explored also the relationship
between its concentrations in the sampled regions and cingulate gyri thickness.
Analyses assessing these correlations were controlled for age and intracranial volume. Considering
that our a priori primary aim was to explore the effect of Glu/Cr or Glx/Cr on neuronal atrophy of the
defined regions involved in pain processing, for all pairwise comparisons and correlation analyses,
the level of significance was set to p ≤ 0.01, with no adjustment for multiple comparisons.
3. Results
3.1. Relationship between Metabolites and Brain Structural Data
The results of the significant relationships between the structural data and metabolites are
summarized in the Table 2.
Frontal regions: on the left side, the Glu/Cr ratio was negatively related to the CT of the inferior
frontal gyrus in its pars opercularis and triangularis (p = 0.01) (Figure 2). Moreover, the Glx/Cr ratio of the
left VLPFC was negatively related to the CT of the left middle anterior cingulate gyrus (mACG) (p = 0.003).
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Table 2. Association between metabolites’ ratio values, cortical thickness and subcortical volumes.
Metabolite rho p-Value
Left VLPFC - - -
Opercular part of the inferior frontal gyrus CT Glu/Cr −0.75 0.010
Triangular part of the inferior frontal gyrus CT Glu/Cr −0.70 0.010
Middle anterior part of the cingulate gyrus CT Glx/Cr −0.81 0.003
Right thalamus - - -
SubCortGrayVol Glu/Cr −0.78 0.002Brain Sci. 2020, 10, x FOR PEER REVIEW 6 of 12 
 
Figure 2. The Spearman’s correlation of Glu/Cr in the left VLPFC and cortical thickness of the 
opercular (a) and triangular (b) parts of the left inferior frontal gyrus (residuals). 
Thalamic regions: a significant negative relationship was found between the Glu/Cr levels in the 
right thalamus with the subcortical GM volume (p = 0.002; r = −0.78) (Figure 3). 
 
 
Figure 3. Correlation between metabolite ratios and cortical thickness. (a) The Spearman’s correlation 
of Glx/Cr in the left VLPFC and cortical thickness of left middle anterior part of the cingulate gyrus 
(residuals); (b) Spearman’s correlation of Glu/Cr in the right thalamus and subcortical gray matter 
volume (residuals). 
3.2. Structural Differences and Clinical Relationships 
As expected, the CT analysis revealed several regions of significant lower regional values in FM 
patients compared with HC. These regions included, the left anterior cingulate gyrus (ACG), the right 
mid-posterior cingulate gyrus (pMCG), and right inferior occipital gyrus (Figure 4). The p-values of 
significant differences between the patients and HC are summarized in the Table 3. 
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3.2. Structural Differences and Clinical Relationships
As expected, the CT analysis revealed several regions of significant lower regional values in FM
patients compared with HC. These regions included, the left anterior cingulate gyrus (ACG), the right
mid-posterior cingulate gyrus (pMCG), and right inferior occipital gyrus (Figure 4). The p-values of
significant differences between the patients and HC are summarized in the Table 3.Brai  Sci. 2020, 10, x FOR PEER REVIEW 7 of 12 
 
Figure 4. Cortical Thickness differences in cingulate gyrus subparts between fibromyalgia (FM) 
patients (red boxes) and healthy controls (blue boxes). On each box, the horizontal line is the median 
and the edges of the box are the 25th and 75th percentiles. The p-value was determined by the two-
tailed t-test for independent samples. (a) Left anterior cingulate gyrus; (b) middle posterior part of 
the right cingulate gyrus. 
Table 3. The mean and standard deviation (sd) of the variables for cortical thickness, separately for 
controls and FM patients. Significant p-value were considered for p ≤ 0.01. 
Cortical Regions 
Controls 
(mean 
mm2 ± sd) 
FM 
Patients 
(mean ± 
sd) 
p-Value 
Left hemisphere   
Anterior part of the cingulate gyrus and sulcus 2.78 ± 0.17 2.61 ± 0.14 0.007 
Right hemisphere   
Inferior occipital gyrus and sulcus 2.66 ± 0.17 2.46 ± 0.19 0.009 
Middle posterior part of the cingulate gyrus and sulcus 2.68 ± 0.09 2.49 ± 0.12 <0.001 
4. Discussion 
As expected, we found a negative association between Glu levels and CT in the corresponding 
brain region. In particular, higher left VLPFC Glu/Cr concentrations, previously reported in the same 
group of patients [12], related in a negative way to the CT values of the inferior frontal gyrus of the 
same side. This corroborates the hypothesis that the previously detected neurochemical and 
structural abnormalities reported in FM are related to each other and can synergistically contribute 
to the pathophysiology of FM. Although we assessed the ratios of metabolites on Cr, we suppose that 
the relationships between metabolites and CT are driven by increased levels of Glu and Glx, 
respectively, and not by a reduction in Cr because the absolute Cr levels were homogeneous among 
patients, as we previously found [12]. 
The VLPFC, part of the prefrontal cortex, is located on the inferior frontal gyrus, being attributed 
to the anatomical structures of Brodmann’s areas 47, 45 and 44, anatomically defined as the orbitalis, 
triangularis and opercularis part, respectively. Although we did not find significant CT differences 
at the inferior frontal gyrus between groups, we interestingly detected negative relationships 
between the Glu/Cr levels revealed on the left VLPFC and its subregions (opercularis and triangularis 
Figure 4. Cortical Thickness differences in cingulate gyrus subparts between fibromyalgia (FM) patients
(red boxes) and healthy controls (blue boxes). On each box, the horizontal line is the median and the
edges of the box are the 25th and 75th percentiles. The p-value was determined by the two-tailed
t-test for independent samples. (a) Left anterior cingulate gyrus; (b) middle posterior part of the right
cingulate gyrus.
Table 3. The mean and standard deviation (sd) of the variables for cortical thickness, separately for
controls and FM patients. Significant p-value were considered for p ≤ 0.01.
Cortical Regions Controls(Mean mm2 ± SD)
FM Patients
(Mean ± SD) p-Value
Left hemisphere
Anterior part of the cingulate gyrus and sulcus 2.78 ± 0.17 2.61 ± 0.14 0.007
Right hemisphere
Inferior occipital gyrus and sulcus 2.66 ± 0.17 2.46 ± 0.19 0.009
Middle posterior part of the cingulate gyrus and sulcus 2.68 ± 0.09 2.49 ± 0.12 <0.001
4. Discussion
As expected, we found a negative association between Glu levels and CT in the corresponding
brain region. In particular, higher left VLPFC Glu/Cr concentrations, previously reported in the
same group of patients [12], related in a negative way to the CT values of the inferior frontal gyrus
of the same side. This corroborates the hypothesis that the previously detected neurochemical and
structural abnormalities reported in FM are related to each other and can synergistically contribute to
the pathophysiology of FM. Although we assessed the ratios of metabolites on Cr, we suppose that the
relationships between metabolites and CT are driven by increased levels of Glu and Glx, respectively,
and not by a reduction in Cr because the absolute Cr levels were homogeneous among patients, as we
previously found [12].
The VLPFC, part of the prefrontal cortex, is located on the inferior frontal gyrus, being attributed
to the anatomical structures of Brodmann’s areas 47, 45 and 44, anatomically defined as the orbitalis,
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triangularis and opercularis part, respectively. Although we did not find significant CT differences at
the inferior frontal gyrus between groups, we interestingly detected negative relationships between the
Glu/Cr levels revealed on the left VLPFC and its subregions (opercularis and triangularis subparts) of
the same side (Figure 2). Interestingly, although we also detected higher Glu/Cr levels within the right
VLPFC, no significant relations were found with the CT on the corresponding region. The different
results of VLPFCs, although may be related to the small patient sample explored, could be also
explained by a possible different response of both areas to the chronic pain [19,20].
Moreover, consistent with previous studies, we confirmed the implication of the cingulate cortex
in FM. We found a reduction in the CT of the left anterior cingulate gyrus (ACG). Indeed, a reduction
in the cortical GM volume in multiple subparts of the CG was widely reported [21–24], in association
with the pain score. In particular, the whole rostral ACG (defined as the totality of anterior CG and
middle CG) is considered to be one of the key regions implicated in FM disease. In HC, together
with the precuneus, occipital cortex [21] and amygdala, the AC cortex is considered responsible
for the descending control of pain. FM patients failed to activate it [25], showing also a decreased
connectivity in this pain descending inhibitory network during resting state studies in a default model
network [21,26]. In addition, we detected a significant decrease in the right middle posterior cingulate
gyrus (pMCG) in FM subjects (p = 0.0001). This region is related to orienting the body toward nocuous
stimuli, the non-affective component of pain processing, and contributes to the retraction reaction
from pain [27]. Moreover, the pMCG has been reported to be involved in several chronic somatic pain
disorders [28].
Moreover, although our spectra were not located in the cingulate gyrus, we found a strong
negative relationship between Glx/Cr in the left VLPFC and the left aMCG (Figure 3). Relationships
of N-acetylaspartate, Glu and myo-inositol in the ACG to the physiology of pain and treatment with
morphine were described [29], but patients suffering from chronic pain displayed only high levels
of Glx and Glx/Cr both in anterior than posterior CG [30,31]. Although there were no significant
differences in the CT between patients and HC (p = 0.014) in the left aMCG, the strong negative relation
we found with Glx/Cr (p = 0.003) could suggest that the toxic effect of high Glu concentrations impacts
also on the other regions implicated in pain processing. From a functional standpoint, it represents a
hub, where information about pain could be linked to motor centres responsible for expressing emotion
on the face and coordinating aversively motivated instrumental behaviours [32]. However, due to
the small patient sample and the not-perfect correspondence between the VOI and the region, further
studies should confirm these data.
Interestingly, no correlations were detected between thalami volumes and Glu/Cr at that level.
Indeed, in our previous report, we did not find differences between groups in metabolites and their
ratios at the thalamus level, strengthening the opinion that Glu could be toxic only at abnormally high
concentrations. On the other hand, we found a relation between Glu/Cr in the right thalamus with the
total subcortical gray volume. This could reflect how Glu impacts on the overall subcortical regions
but not directly on thalami. Further studies, using a multi-voxel spectroscopy approach, could better
evaluate this hypothesis.
However, there is strong a priori evidence that Glu excesses can lead to neuronal dysfunction
and cell loss, so the relationship we found in this study is interesting and can shed new light into
the pathophysiology of FM. In pharmacological and cellular models, all Glu agonists (ionotropic
and metabotropic) cause neuronal apoptosis in a dose-dependent manner [8]. Moreover, abnormally
high levels of Glu, resulting from increased release and/or decreased removal at the synapses, lead to
degeneration and neuronal death [9,10]. The neurotoxic effects of excessive Glu receptor activation have
been widely described also in many other conditions including epilepsy, stroke, traumatic brain and
spinal cord injury and amyotrophic lateral sclerosis [33]. Glu is the primary excitatory neurotransmitter
in the brain, and it is found in approximately 60% of neurons. It is known that synaptic Glu is taken up
by astrocytes, where it is converted to glutamine and transported to neurons for the production of
Glu or GABA [34]. The implication of glutamatergic neurotransmission in pain processing has been
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proposed. Indeed, the development of neuropathic pain in preclinical models is thought to be a result
of central sensitization, or central plasticity, involving both ionotropic and metabotropic glutamate
receptors [4]. Higher Glx and Glu levels within the brain of FM patients have been reported by
different groups in several regions, including the amygdala, the posterior cingulate, VLPFC, posterior
insula and hippocampus [5]. Moreover, volumetric reductions in these brain regions in FM have been
largely described in structural MRI studies [35], but without exploring the metabolites concentrations.
However, the Glu elevation does appear specific. Indeed, not every region examined presented this
finding. In particular, no elevations have been detected in the anterior insula [36] or the prefrontal
cortex [30]. Thus, a topographic distribution of a higher Glu level could be responsible for the atrophic
pattern described in this condition playing a role in chronic pain symptoms through neuroplastic
changes as detected in animal models [4].
Considering H-MRS and structural studies performed in the same group of FM patients, only a
sub-part of a study explored the correlation between Glx changes in the anterior and posterior insula
and GM changes after pregabalin administration [37], without finding a significant relationship.
Interestingly, the same study found GM reduction in the bilateral insula after pregabalin administration,
that was also associated with concomitant reductions in connectivity to the default mode network,
and with reduced clinical pain. They speculated that the decreased GM volumes were due to the
decreased Glu synapse number. Relative to controls, patients with FM also showed abnormalities in
many brain areas as in previous structural neuroimaging studies [11,20,30]. Brain plasticity in the form
of increased/decreased GM has been observed in FM [11]. Ceko et al. demonstrated how fibromyalgia
interacts with age to produce distinct patterns of gray matter differences, which specifically increases
in younger and decreases in older patients, suggesting that the brain structure and function shift from
being adaptive in younger to being maladaptive in older patients [38]. Hence, to test the impact of the
glutamatergic system on CT and subcortical volumes, we controlled the results for age and intracranial
volume. Considering other cortical regions, we found a strong reduction in the right inferior occipital
gyrus in the FM group. This result is consistent with the literature, where indeed these regions were
previously reported to be altered in the pain-processing network in FM patients [39,40].
Limitations
Our empirical data analysis study has several limitations. First of all, the small group sample size
may limit the generalizability of our findings. However, the groups were matched for sex and age,
and the cohort is similar to those used in studies of other advanced neuroimaging techniques in FM.
Due to the retrospective design of the study (enrolment in 2010), patients were selected using the 1990
ACR criteria for the diagnosis of FM. Further studies should select patients using more recently revised
diagnostic criteria carrying a higher specificity for FM diagnosis and chronic widespread pain [41,42]
that may be reflected by changes in glutamatergic neurosignaling. We also did not collect information
on depression and anxiety symptoms, which may be a potential confounder in any findings related
to the role of Glu and regional thickness [40,43]. Considering the spectra, one of the limits is the
relatively large size of the H-MRS voxels, but this is required to achieve an adequate signal-to-noise
ratio for the quantification of Glu and Glx using the PRESS technique at a 3T field strength. Such large
voxels inevitably contain substantial quantities of GM in which the majority of glutamatergic activity
occurs, white matter that has less Glu and CSF which contains insignificant amounts of Glu. Moreover,
this technique does not differentiate between intracellular and extracellular components, indeed its
coediting is limited to the macromolecular signal. However, this study was based on prior observations
of a strong association between Glu concentrations and brain atrophy and we therefore interpret our
observations as representing actual Glu levels. Indeed, this study provides the first (to our knowledge)
promising in vivo evidence of a direct negative relationship between glutamate and regional CT in
FM. Therefore, future studies with larger sample sizes are needed to improve the statistical power and
verify these observations.
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5. Conclusions
Our study is the first, to our knowledge, to show a negative correlation between Glu/Cr levels
and brain regional structural changes in FM. Although these results are far from conclusive, they do
support a role for Glu in the pathophysiology of FM. Prospective studies with larger sample sizes
are needed to confirm these results and to validate this method. We anticipate that clinical research
should investigate these aspects of FM in order to better understand the long-term effects of pain on
the central nervous system to investigate new therapeutic options. In particular, the development of
new therapeutic approaches that aim to limit the effect of Glu-mediated neurotoxicity, thus mediating
the clinical severity and progression of FM, is desirable in the near future.
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